VO659

DRUG2 trials

Sponsors

Vico Therapeutics B.V., Vico Therapeutics B. V.

Conditions

3 and Huntington's diseaseHuntington DiseaseSpinocerebellar Ataxia Type 1Spinocerebellar Ataxia Type 3Spinocerebellar ataxia types 1

Phase 1

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

RecruitingNCT05822908

Vico Therapeutics B. V.Huntington Disease, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3

Start: 2023-02-14End: 2028-10-15Target: 68Updated: 2026-08-19

A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with spinocerebellar ataxia types 1, 3 and Huntington’s disease

RecruitingCTIS2024-514328-18-00

Vico Therapeutics B.V.3 and Huntington's disease, Spinocerebellar ataxia types 1

Start: 2022-12-06Target: 40Updated: 2026-01-19

Related Papers

Longitudinal Changes of Clinical, Imaging, and Fluid Biomarkers in Preataxic and Early Ataxic Spinocerebellar Ataxia Type 2 and 7 Carriers

Neurology2024-08-128 citations